These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23659854)

  • 1. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
    Gomes-da-Silva LC; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):356-64. PubMed ID: 23659854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
    Reagan-Shaw S; Ahmad N
    FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of PLK-1 silencing on endothelial cells and cancer cells of diverse histological origin.
    Gomes CP; Gomes-da-Silva LC; Ramalho JS; de Lima MC; Simões S; Moreira JN
    Curr Gene Ther; 2013 Jun; 13(3):189-201. PubMed ID: 23531193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
    Bu Y; Yang Z; Li Q; Song F
    Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
    Charbe NB; Amnerkar ND; Ramesh B; Tambuwala MM; Bakshi HA; Aljabali AAA; Khadse SC; Satheeshkumar R; Satija S; Metha M; Chellappan DK; Shrivastava G; Gupta G; Negi P; Dua K; Zacconi FC
    Acta Pharm Sin B; 2020 Nov; 10(11):2075-2109. PubMed ID: 33304780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
    Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.
    Sakurai Y; Hatakeyama H; Akita H; Harashima H
    Mol Pharm; 2014 Aug; 11(8):2713-9. PubMed ID: 24800640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Enhancive effect of PLK1 gene silencing on sensitivity of K562/A02 cells to adriamycin].
    Liu L; Zhang M; Zou P; Tian L; Liu F
    Ai Zheng; 2006 Apr; 25(4):404-8. PubMed ID: 16613670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.
    Kolosenko I; Edsbäcker E; Björklund AC; Hamil AS; Goroshchuk O; Grandér D; Dowdy SF; Palm-Apergi C
    J Control Release; 2017 Sep; 261():199-206. PubMed ID: 28684168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment.
    Gomes-da-Silva LC; Santos AO; Bimbo LM; Moura V; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
    Int J Pharm; 2012 Sep; 434(1-2):9-19. PubMed ID: 22617794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy.
    Li Y; Liu R; Yang J; Ma G; Zhang Z; Zhang X
    Biomaterials; 2014 Dec; 35(36):9731-45. PubMed ID: 25189519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipopolyplexes comprising imidazole/imidazolium lipophosphoramidate, histidinylated polyethyleneimine and siRNA as efficient formulation for siRNA transfection.
    Gonçalves C; Berchel M; Gosselin MP; Malard V; Cheradame H; Jaffrès PA; Guégan P; Pichon C; Midoux P
    Int J Pharm; 2014 Jan; 460(1-2):264-72. PubMed ID: 24225347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
    Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
    Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of PLK1 gene silence on cell cycle, proliferation and drug resistance in K562/A02 cells].
    Liu L; Zhang M; Zou P; Tian L; Liu F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):241-6. PubMed ID: 16638189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Knockdown of PLK1 mRNA by special siRNA].
    Chen GX; Dong QH; Zhang JW; Fu FF; Xu ZF; Liang QY; Zheng S; Ding JY
    Yi Chuan; 2006 Jan; 28(1):21-5. PubMed ID: 16469711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
    Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
    Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
    Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
    Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
    Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of silencing Polo-like kinase 1 on migration and invasion of colorectal cancer cells].
    Han DP; Cui JT; Lu AG; Chen XH; Feng B; Zong YP; Qu S; Cao QF; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2011 Jan; 14(1):61-4. PubMed ID: 21271384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.